Log in with your email address username.


[Correspondence] STAMPEDE trial and patients with non-metastatic prostate cancer

The study by Nicholas James and colleagues (March 19, p 1163)1 shows that the addition of docetaxel to androgen deprivation therapy improved survival in patients with hormone-sensitive metastatic, high-risk, node-positive, or recurrent prostate cancer. Even though these findings support the emerging role of chemotherapy plus hormonal treatment in the metastatic setting, their generalisability to men with non-metastatic prostate cancer might be questioned. Although androgen deprivation therapy is the standard of care in M+ disease, local treatments represent an important step of the therapeutic approach high-risk prostate cancer.